Israel to test oral COVID-19 vaccine.
Image Credit: Oramed Pharmaceuticals
An Israeli company will soon start trials for oral COVID-19 vaccine and will become the firat country to do so. The company, Oramed Pharmaceuticals, will start clinical trials at Tel Aviv Sourasky Medical Center upon approval from Health Ministry, which will take a few weeks.
The company already GMP manufactured thousands of capsules in Europe which woul d be available for the Israeli trial and also for other countries.
The oral COVID-19 vaccine is based on Oramed’s “POD” oral delivery technology and also Premas’s vaccine technology. The oral vaccine targets three structural proteins of the novel coronavirus rather than targeting one spike protein via the current Pfizer and Moderna’s vaccine. This would make the oral vaccine stronger than the current vaccines as it would be more resistant to new variants.
This vaccine should be much more resistant to COVID-19 variants. Even if the virus gets through one line, there is a second line, and if through the second line, there is a third.
Oramed Pharmaceuticals CEO Nadav Kidron.
The oral vaccine is being tested against a number of variants including the Delta variant. If they succeed in the trials the oral vaccine would eliminate barriers to rapid, wide- scale distribution according to the CEO.
An oral COVID-19 vaccine would eliminate several barriers to rapid, wide-scale distribution, potentially enabling people to take the vaccine themselves at home. While ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the case that a COVID-19 vaccine may be recommended annually like the standard flu shot.
Oramed Pharmaceuticals CEO Nadav Kidron.
Also, oral medications tend to have fewer side effects and does not require professional administration, allowing individuals to take the vaccine in the comfort of their own home.
Share this:
What Now News 24 
1 Comment »